生物制药公司Viking Therapeutics, Inc.（VKTX）今日盘前大跌8.2%，主要受到公司最新季度财报不及预期的影响。这一跌幅远超昨日夜盘5.36%的跌幅，反映出投资者对公司财务状况的担忧程度进一步加深。
根据公司公布的财报，截至6月30日的季度，Viking Therapeutics调整后每股亏损为58美分，远超分析师平均预期的45美分亏损。公司当季净亏损高达6556万美元，相比之下，去年同期每股亏损仅为20美分。这一业绩表现大大低于华尔街分析师的预期，预期区间为每股亏损30至55美分。
尽管Viking Therapeutics在生物技术领域有着潜力巨大的研发管线，但持续的巨额亏损引发了投资者对公司短期财务状况的担忧。值得注意的是，尽管公司股价在本季度上涨了21.1%，但今年迄今为止仍下跌了20.2%。目前，分析师对该股票的平均评级仍维持在"买入"，12个月目标价中位数为101.00美元，较当前股价有显著上涨空间。然而，这次财报的不佳表现可能会影响部分分析师对公司的评估，投资者应密切关注后续的分析师报告和评级变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.